What longer-wear monitoring, fewer sensor changes and tighter integration could mean for future CGM and pump choices.
Image courtesy of Senseonics.
Senseonics has announced that their first commercial patient is now using the Eversense 365 CGM integrated with Sequel MedTech’s twiist™ hybrid-closed loop insulin delivery system, marking an important step in the development of longer-term diabetes technology.
This is the first time a 365-day CGM has been paired with a hybrid-closed loop system, combining an implantable glucose sensor with automated insulin adjustment. The companies say the integration is designed to offer greater flexibility and personalisation, while reducing the disruption caused by frequent sensor changes and device re-pairing.
What makes this different?
Eversense 365 is currently the only implantable CGM available, providing up to 365 days of glucose monitoring from a single sensor insertion carried out by a healthcare professional. Unlike traditional CGMs that require replacement every 7–14 days, the system aims to minimise interruptions while maintaining high accuracy over a full year.
When used with the twiist hybrid-closed loop system, glucose data from Eversense 365 feeds directly into the twiist Loop algorithm, which automatically adjusts insulin delivery based on real-time sensor readings and predicted glucose levels. This is intended to reduce day-to-day decision-making and support more stable glucose management.
The twiist system also includes iiSure™ technology, which directly measures the volume of insulin delivered. According to Sequel MedTech, this allows for faster occlusion detection—up to nine times quicker than some existing systems—and greater confidence that insulin is being delivered as intended.
Choice and personalisation
Senseonics CEO Tim Goodnow said the integration focuses on simplifying diabetes management without sacrificing reliability.
“Patients and clinicians want dependable, long-term glucose data to support insulin delivery decisions. Integrating Eversense 365 with the twiist hybrid-closed loop system is a major step towards more personalised and lower-maintenance diabetes management.”
Sequel MedTech CEO Alan Lotvin highlighted the importance of expanding choice:
“Diabetes management is deeply personal, and no single approach works for everyone. Integrating twiist with the Eversense CGM supports our focus on precision, confidence and choice for people using hybrid-closed loop systems.
Availability
While the first commercial PWD is already using the integrated system, broader availability of twiist with Eversense 365 is expected by March 2026, subject to regulatory approvals, clinical adoption and funding decisions.
Plans for the UK and Europe
Senseonics has just obtained a CE-Mark i.e. European regulatory approval, and now plans tostart selling the implant in Germany, Italy, Spain and Sweden in the coming months. The company's plans for a rollout of the Eversense 365 system in the UK are not yet known.
__________
Disclaimer
Blogs and publications on this website are independent of any involvement by medtech companies or diabetes related charities. To ensure there is no bias, we do not accept any products, freebies or other material from any medtech provider. Except where credited otherwise, all materials are copyright ©️What CGM.
What CGM is not associated or affiliated with Abbott or FreeStyle Libre. Content here and on our websitewww.whatcgm.com does not constitute medical advice or replace the relationship between you and healthcare professionals nor the advice you receive from them.
The author of this blog has type 1 diabetes and uses a CGM on NHS prescription.
Leave a comment (all fields required). Please note, we are unable to respond to individual comments posted here.